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ABSTRACT
Background: Mycobacterium tuberculosis rapid diagnostic tests (RDTs) are widely
employed in routine laboratories and national surveys for detection of rifampicin-
resistant (RR)-TB. However, as next-generation sequencing technologies have
become more commonplace in research and surveillance programs, RDTs are being
increasingly complemented by whole genome sequencing (WGS). While comparison
between RDTs is difﬁcult, all RDT results can be derived from WGS data. This
can facilitate continuous analysis of RR-TB burden regardless of the data generation
technology employed. By converting WGS to RDT results, we enable comparison of
data with different formats and sources particularly for low- and middle-income
high TB-burden countries that employ different diagnostic algorithms for drug
resistance surveys. This allows national TB control programs (NTPs) and
epidemiologists to utilize all available data in the setting for improved RR-TB
surveillance.
Methods: We developed the Python-based MycTB Genome to Test (MTBGT) tool
that transforms WGS-derived data into laboratory-validated results of the primary
RDTs—Xpert MTB/RIF, XpertMTB/RIF Ultra, GenoType MDRTBplus v2.0, and
GenoscholarNTM+MDRTB II. The tool was validated through RDT results of
RR-TB strains with diverse resistance patterns and geographic origins and applied on
routine-derived WGS data.
Results: TheMTBGT tool correctly transformed the single nucleotide polymorphism
(SNP) data into the RDT results and generated tabulated frequencies of the RDT
probes as well as rifampicin-susceptible cases. The tool supplemented the RDT
probe reactions output with the RR-conferring mutation based on identiﬁed SNPs.
The MTBGT tool facilitated continuous analysis of RR-TB and Xpert probe reactions
from different platforms and collection periods in Rwanda.
Conclusion: Overall, the MTBGT tool allows low- and middle-income countries to
make sense of the increasingly generated WGS in light of the readily available RDT
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results, and assess whether currently implemented RDTs adequately detect RR-TB
in their setting. With its feature to transform WGS to RDT results and facilitate
continuous RR-TB data analysis, the MTBGT tool may bridge the gap between and
among data from periodic surveys, continuous surveillance, research, and routine
tests, and may be integrated within the national information system for use by
the NTP and epidemiologists to improve setting-speciﬁc RR-TB control.
The MTBGT source code and accompanying documentation are available at
https://github.com/KamelaNg/MTBGT.
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INTRODUCTION
Resistance to rifampicin (RIF), the most potent anti-tuberculosis (TB) drug, hampers
TB control. RIF-resistant (RR)-TB persists as an urgent public health crisis as only 29% of
estimated RR-TB patients worldwide were detected and notiﬁed in 2017. Further, 18%
of previously treated TB patients were found to have RR-TB (WHO, 2018). The
WHO endorsed the following rapid molecular RR-TB diagnostic test (RDTs) to address
this concern: Xpert MTB/RIF (Xpert Classic) and the new version Xpert MTB/RIF Ultra
(Ultra) (Cepheid, Sunnyvale, CA, USA) which employ heminested real-time polymerase
chain reaction and molecular beacon technology (Blakemore et al., 2010); and the line
probe assays—GenoType MDRTBplus v2.0 (hereinafter called LPA-Hain) (Hain
Lifescience GmbH, Nehren, Germany); and GenoscholarNTM+MDRTB II (hereinafter
called LPA-Nipro) (NIPRO Corporation, Osaka, Japan) which rely on multiplex
ampliﬁcation and reverse hybridization of target to both wild-type and mutant probes on a
membrane strip (Dheda et al., 2017). These tests were designed to detect RR-conferring
mutations within the RIF resistance determining region (RRDR) or hotspot of the rpoB
gene (Andre et al., 2017; Blakemore et al., 2010; Ng et al., 2018a, 2018c).
The Xpert assay involves binding of ﬁve short overlapping ﬂuorescent probes to
wild-type regions of the RRDR. Each of the ﬁve probes corresponds to several mutations
which inhibit probe binding, thereby disrupting the signal from the respective probe.
Thus, when a mutation is detected by Xpert, at least one probe does not bind. Certain
mutations which completely interfere with probe binding result in “drop-out” or absent
probe, whereas mutations that allow limited probe hybridization are represented by
“delayed” probes (Blakemore et al., 2010). Xpert probes are therefore often considered as a
proxy for circulating RIF resistance-conferring mutations which may be common or
infrequent in a particular country. Understanding their frequency can be crucial for RIF
resistance surveillance. For example, mutation Ser450Leu repeatedly detected globally
(Coll et al., 2018; Walker et al., 2015) is captured by “absent” Xpert probe E (Ng et al.,
2018a).
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The implementation of Xpert was a breakthrough in TB diagnosis as it revolutionized
the detection of RR-TB worldwide, allowing for prompt identiﬁcation of patients who need
to undergo adapted treatment. Xpert Classic is the most widely deployed RDT globally,
implemented as the initial diagnostic tool for all presumptive pulmonary TB patients by
32 out of 48 high TB-burden countries (WHO, 2018). The wide utilization of the tests in
both low and high burden TB countries resulted in the production of large volumes of
RDT data, although comparisons within and between countries can be difﬁcult due to use
of differing technologies.
The utility of next-generation sequencing technologies has been widely studied for
improved detection of drug-resistant TB in diverse laboratory settings worldwide (Gardy &
Loman, 2018). Next-generation sequencing-based whole genome sequencing (WGS)
ofMycobacterium tuberculosis (Mtb) has been shown to accurately detect RR-TB by calling
relevant single nucleotide polymorphisms (SNPs) in the rpoB gene (Coll et al., 2018;
Miotto et al., 2017). Whole genome sequencing is already being widely implemented in
the United Kingdom, the Netherlands, and New York, aimed towards completely
replacing phenotypic drug susceptibility testing in the clinic (CRyPTIC Consortium and
the 100,000 Genomes Project et al., 2018; de Viedma, 2019). Whole genome sequencing
implemented in high burden TB countries was shown to accurately estimate the
prevalence of DR-TB (Zignol et al., 2018). The conventional periodic TB drug resistance
surveys have been gathering data representative of the Mtb population in poor
resource settings, while high-income countries typically apply continuous surveillance
(WHO, 2018; Zignol et al., 2018), to help improve the choice of standard TB treatment
before full drug sensitivity proﬁle is known (WHO, 2018).
The increasing use of WGS in research and public health initiatives can lead to a
disconnect from the RDT-based data being generated routinely in the clinic, and the
majority of surveys, widening the Mtb data gap. We aim to bridge this Mtb data gap by
transforming WGS data into each of the related RDT data outputs, to facilitate analysis of
RR-TB prevalence and underlying mutations regardless of the switch between data
generation technologies. This will allow end-users to compare “apples with apples,” and
analyze previous historical strains with current isolates representative of the entire TB
patient population in the country.
We present the MycTB Genome to Test (MTBGT) tool, a Python 3-based set of scripts
that rapidly transform WGS data type into RDT and mutation reports. The modules
automatically generate frequencies of RIF-susceptible (RS) and RR-TB samples detected
and supplement the RDT probes output with the detected RR-conferring mutation in the
format of “wild-type amino acid-codon number-mutant amino acid.”
MATERIALS AND METHODS
We developed the MTBGT tool, a Python 3-executable that convertsMtbWGS data in the
form of variant call format (VCF) or MTBseq (Kohl et al., 2018) tab ﬁles into the most
likely output that would be observed from Xpert Classic, Xpert Ultra, LPA-Hain, and
LPA-Nipro based on previously validated work (Ng et al., 2018a, 2018c). The MTBGT tool
can be accessed at https://github.com/KamelaNg/MTBGT.
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The MTBGT tool
The MTBGT tool can be run on any python 3-enabled operating system with no additional
prerequisites. The MTBGT workﬂow is shown in Fig. 1. The input is a folder of ﬁles
derived from an SNP calling pipeline, either in standard raw VCF format or tab format
as output from MTBseq. The MTBGT tool assumes the standard H37Rv NC000962.3
genome was used for calling these SNPs. If not, the user may remap the genome positions
to the speciﬁc RR-TB-related codons using a tab-delimited mapping ﬁle. An example
of this tab-separated ﬁle is bundled with the tool. By default, the module will run all the
RDTs on the input ﬁles.
The generated tab-delimited output ﬁle includes the Sample name, RIF resistance or
susceptibility, the associated mutant codon position and mutation pattern, and a series of
0’s or 1’s indicating absence or presence of the capturing probe for the RDTs, and the
RR-conferring mutation (an example output is given in Table 2). A summary table with
counts and proportions of detected RS-TB cases, RDT probes, and RR-conferring
mutations is also generated (Table S1). These tab-separated output ﬁles can be easily
imported into Excel as outlined in the associated manual.
Validation and sample application of the MTBGT modules
We simulated VCF ﬁles for internal validation of the MTBGTmodules. We then randomly
chose a VCF ﬁle and edited it in Notepad++ 7.6.3 (https://notepad-plus-plus.org/) to
contain all previously tested and validated RR-conferring mutations (Andre et al., 2017;
Miotto et al., 2017) which were mapped to known RDT results (Ng et al., 2018a, 2018c)
(Table 1). We generated ﬁles with single and multiple RR mutations to ensure the tool
is robust for all scenarios. These simulated VCFs are provided with the tool.
To show real-world applicability, the MTBGT tool was run on WGS of RS and RR-TB
WHO Tropical Disease Research (TDR) strains with diverse resistance patterns and
geographic origins stored in the Belgian Coordinated Collections of Microorganisms in the
Institute of Tropical Medicine including the 47 TDR-TB strains tested in the previous
validation of the RDTs against the available rpoB Sanger sequences of the strains
Figure 1 The MTBGT tool workﬂow. Full-size DOI: 10.7717/peerj.7564/ﬁg-1
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(Ng et al., 2018a, 2018c; Vincent et al., 2012). The fastQ ﬁles (ENA accession PRJEB31023)
for these samples were run through the MTBseq pipeline with default settings (Kohl
et al., 2018) to generate the tab ﬁles for input to MTBGT. Additionally, WGS from
Table 1 Rifampicin resistance (RR)-conferring mutations and associated rapid diagnostic test (RDT) results, previously tested and validated*,
and used as basis for developing the MTBGT tool.
RR-TB RDT RR mutation













ND ND ND ND ND ND ND Val170Phe
Probe A rpoB1 3.5 WT1 S1 Ser428Arg
Probe A rpoB1 5.9–6.3 WT2 S1 Leu430Pro
Probe A, Probe B rpoB1 2.9 WT2 S1 Ser431Gly
Probe B rpoB1 3.4 WT2, WT3 S1 Gln432Glu
Probe B rpoB2 3.2 WT3 S2 Met434Ile
Probe B rpoB2 3.3 WT3 S2 Met434Thr
Probe B rpoB1 6.3 WT3 S2 Met434Val
Probe B rpoB2 2.8 WT3, WT4 S2 Asp435Glu
Probe B delayed rpoB2 5.3 WT3, WT4 S2 Asp435Phe
Probe B rpoB2 3.3 WT3, WT4 S2 Asp435Gly
Probe B rpoB2 3.5–3.7 WT3, WT4 MUT1 S2 R2 Asp435Val
Probe B delayed rpoB2 4.0–4.4 WT3, WT4 S2 Asp435Tyr
Probe C rpoB2 6.4 WT4 S2 Asn437Asp
Probe C rpoB2; rpoB3 3.0; 2.3 WT5, WT6 S3 Ser441Leu
Probe C rpoB2; rpoB3 4.7; 2.3 WT5, WT6 S3 Ser441Gln
Probe D rpoB3 3.7–3.9 WT7 MUT2B S4 R4b His445Asp
Probe D rpoB3 4.9 WT7 S4 His445Gly
Probe D rpoB3 3.5–3.6 WT7 S4 His445Leu
Probe D rpoB3 3.4–3.5 WT7 S4 His445Asn
Probe D rpoB3 3.6 WT7 S4 His445Gln (CAG)
Probe D rpoB3 4.1 WT7 S4 His445Gln (CAA)
Probe D delayed rpoB3 1.9 WT7 S4 His445Arg
Probe D rpoB3 4.7 WT7 S4 His445Ser
Probe D rpoB3 4.9 WT7 S4 His445Thr
Probe D rpoB3 3.2–3.3 WT7 MUT2A S4 R4a His445Tyr
Probe D rpoB4B 5.0 WT7 S4 Lys446Gln
Probe E rpoB3 4.0 WT8 S5 Ser450Phe
Probe E rpoB3; rpoB4A 2.5–2.9; 6.0–6.5 WT8 MUT3 S5 R5 Ser450Leu
Probe E rpoB3; rpoB4A 2.3–2.7; 3.3–3.7 WT8 S5 Ser450Trp
Probe E delayed rpoB4B 5.7–6.1 WT8 S5 Leu452Pro
ND ND ND ND ND ND ND Ile491Phe
Notes
* (Ng et al., 2018a, 2018b); Capturing probe, RDT probe associated with the RR-conferring mutation; Melting temperature shift, difference between mutant (MUT) and
wild-type (WT) melting temperatures; ND, ‘not detected’, refers to mutations outside the RR determining region, not detected by the RR-TB RDTs.
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324 phenotypically RR-TB isolates of retreatment TB patients in Kinshasa, the Democratic
Republic of Congo (DRC) collected in 2005–2010 (Meehan et al., 2018), and 233 WGS
isolated 1991–2010 from Rwanda were subjected to the MTBseq pipeline and run through
the MTBGT tool.
We were then able to extract the associated Xpert results from the 1991 to 2010
Rwandan dataset and compare it with actual Xpert results from 2012 to 2017 (Ng et al.,
2018b).
RESULTS
We tested the MTBGT tool on a 64-bit Windows 10 Enterprise computer with a 2.50 GHz
processor and a 8.00 GB of RAM. The running time was 39 milliseconds for one MTBseq
tab ﬁle and 530 milliseconds for a VCF ﬁle.
The MTBGT tool correctly transformed theWGS-derived SNPs in the VCF and MTBseq
tab ﬁles into the laboratory-validated RDT probe reactions (Table 2), and accurately detected
all previously validated RR-conferring mutations in the simulated VCF and MTBseq
clinical WGS data from the TDR, DRC (Figs. 2A and 2B), and Rwanda (Figs. 3A and 3B)
strains, including double nucleotide changes—two SNPs covering two loci or genome
positions—such as the CAC/ AGC and CAC/ TCC His445Ser mutations and
combinations of any two unlinked mutations. The generated frequency and proportion
tables (Table S1) showed the distribution of the RS and RR-TB strains, the RDT probe
reactions, and the RR-conferring mutations detected.
The in silico extracted Xpert results from the Rwandan WGS collected in 1991–2010
revealed that the majority of RR-TB cases detected were linked with Xpert Classic probe E
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(Fig. 3A). This observation was consistent with the actual Xpert results gathered in
2012–2017. Figure 3C shows the distribution of 12 years worth of Xpert results in Rwanda.
The MTBGT tool facilitated this continuous analysis of in silico predicted Xpert results
from 2005 to 2010 WGS and actual Xpert results in 2012–2017, and allowed us to plot
the distribution of absent probe E against the notiﬁed RR-TB cases from surveillance
programs and national surveys in Rwanda. The low WGS sampling reﬂected in Fig. 3C is
Figure 2 Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and
(B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in
Kinshasa, DRC from 2005 to 2010, detected by the MTBGT tool.
Full-size DOI: 10.7717/peerj.7564/ﬁg-2
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Figure 3 Distribution of (A) rifampicin-sensitive samples and Xpert Classic probes, and
(B) rifampicin resistance-conferring mutations among rifampicin-resistant tuberculosis isolates in
Rwanda from 1991 to 2010, determined by the MTBGT tool and (C) distribution of r.
Full-size DOI: 10.7717/peerj.7564/ﬁg-3
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explained by the limited TB cultures kept in the freezer in 2005–2010. Notably, we also
observed the divergence of documented probe reactions from the predominant absent
probe E in 2013–2017.
Xpert Classic probe E was also predominantly seen in samples from Kinshasa, DRC
(Fig. 2A; Table S1). Mutation Ser450Leu, linked with Xpert Classic probe E, was the major
RR-conferring mutation observed in both settings (Figs. 2B and 3B).
DISCUSSION
To make sense of the increasingly produced WGS in light of the existing and readily
available routine RDT results, we developed, validated, and applied the MTBGT, a Python-
implemented tool that extracts RR-TB RDT results and RR-conferring mutations from
WGS-derived SNP data.
If a country performed prior drug resistance surveys with a different diagnostic
algorithm, the MTBGT tool allows for comparing data of different formats and sources,
facilitating analysis of previous and current RR-TB case counts, probe reactions, and
mutations, such as periodic DRS results conducted as cross-sectional surveys, often with
different technology from the previous one. Although WGS data give a much higher
resolution than the RDTs, low- and middle-income high RR-TB burden countries are not
yet capable of implementing routine WGS for all presumptive TB patients due to
limitations in funding and logistic challenges (Meehan et al., 2019). However, RDTs are
used routinely in such countries, producing a wealth of RR-TB data, whereas WGS is used
for regular country-wide drug resistance surveys by the WHO (Zignol et al., 2018), and
implemented in low burden high-income countries. But since RDT results cannot be
upscaled to WGS results, for comparison of these two data sources, WGS must be
downscaled to the RDT results. By downscaling, the MTBGT tool adds to a substantial
history of RDT probe data which ampliﬁes surveillance analyses that can inform national
TB control programs (NTPs) of low- and middle-income settings. This is similar to how
CRISPR-based strain typing of M. tuberculosis (termed spoligotyping) can be predicted
from WGS reads through SpoTyping (Xia, Teo & Ong, 2016). Although spoligotyping is
known to have a lower resolution than WGS for typing, it is still widely used in many
low- and middle-income TB endemic countries due to its low cost (Montoya et al., 2013;
Suzana et al., 2017; Tulu & Ameni, 2018). We foresee our tool being used in a similar
manner, until WGS capabilities become more commonplace in low- and middle-income
high RR-TB burden countries.
We show in Fig. 3C how the MTBGT tool would be beneﬁcial in Rwanda, a low-income
country which uses Xpert for routine diagnostics and WGS for WHO-led 5-year drug
resistance surveys and selected research projects. Figure 3C reﬂects continuous
distribution of RR-TB cases and Xpert absent probe E in Rwanda for more than a decade.
These trends of RR-TB and absent probe E boost surveillance analyses that can inform
the Rwandan NTP and support public health efforts for improved RR-TB control.
The MTBGT tool allows for such comparisons and continuous distributions to be made,
enabling low- and middle-income researchers to utilize all of their data for surveillance of
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RR-TB. This analysis of Rwandan datasets is a proof-of-concept that the MTBGT tool
provides an opportunity to compare and analyze old and new data produced by different
technologies bridging the RR-TB data gap. Care must be taken that the comparison is valid
given the populations sampled. The predominant Xpert Classic probe E observed in
Rwanda is supported by the associated RR mutation Ser450Leu (Tables 1 and 2) being
present in the primary circulating multidrug-resistant TB clone in this setting (Ngabonziza
et al., 2018), and also most frequently associated with global RR-TB (Cohen et al., 2015;
Coll et al., 2018; Georghiou et al., 2016).
Programmatic surveillance is possible with only the RIF susceptibility status
of patients’ samples, but at a different level. The RDT probe information which
represents the underlying RR-conferring mutation provides an added critical value for
epidemiological studies and surveillance (Ng et al., 2018b). This is exempliﬁed by Xpert
probe B and probe binding delay in South Africa being associated with false RR-TB results
(Berhanu et al., 2019). In this setting, patients who were true RS but diagnosed as RR
were treated with less effective and more toxic multidrug-resistant TB drugs relative to the
standard TB treatment. Further, non-routine WGS alone may give incorrect distribution
of circulating mutations in the setting due to culture and sampling biases, as shown by
the limited stored cultures resulting in low WGS sampling in Rwanda in 2005–2010.
Settings which employ different RDTs can refer to Table 1 where they can match
laboratory-validated Xpert Classic and Xpert Ultra probe signatures with a speciﬁc RR-TB
mutation type (Ng et al., 2018a, 2018c). This would be helpful for settings such as South
Africa which implements Xpert Classic and concurrently transitions to Xpert Ultra
(Berhanu et al., 2018), and many other countries that will shift to Xpert Ultra in the near
future, such as Rwanda by 2020.
The genome-based approach of the MTBGT tool also allows for reporting of disputed
mutations that confer occult RR and are frequently missed by the Mycobacterium
Growth Indicator Tube phenotypic DST (Ng et al., 2018a; Van Deun et al., 2015).
For instance, disputed mutation Leu452Pro, epidemiologically linked with an extensively
drug-resistant TB outbreak in KwaZulu-Natal, South Africa in 2005 (Cohen et al.,
2015; Ioerger et al., 2009), was detected in some strains from Kinshasa, DRC, and Rwanda
(Figs. 2B and 3B; Supplemental File). Mutation Leu452Pro is captured by delayed
Xpert Classic probe E, denoting partially inhibited probe E ﬂuorescence (Lawn & Nicol,
2011; Ng et al., 2018a), and speciﬁcally identiﬁed by the unique combination of Xpert
Ultra probe rpoB4B and corresponding melting temperature shift (Table 1), provided
sufﬁcientMtb DNA is detected. Further, mutation Leu452Pro was reported to be missed
in clinical samples by LPA-Hain due to its end-probe location (Al-Mutairi, Ahmad &
Mokaddas, 2011; Rigouts et al., 2013), thus contributing to the RR-TB detection gap. The
ability of the MTBGT tool to rapidly and accurately detect disputed mutations is
therefore important.
As a supplementary feature, the MTBGT tool picks up any RR-conferring mutation
present in the VCF or MTBseq tab ﬁle, and may help assess whether RDTs sufﬁciently
detect RR-TB cases in speciﬁc settings.
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Looking into the future when WGS will be implemented as the primary diagnostic tool
for all presumptive TB patients to conﬁrm TB and/or RR-TB, the MTBGT tool will bridge
the TB data gap by allowing comparison of past Xpert and LPA results with current
in silico predicted results from routine whole genome sequences. These data would be
comparable based on a common statistical parameter and representative of the
presumptive TB population in the setting. With more whole genomes of M. tuberculosis
sequenced, the in silico predicted probe distribution will more accurately capture the
circulation of RR-TB mutations in the setting. The tool can do so by precisely revealing the
divergence of current probes from a previously documented predominant probe over time,
implicative of other circulating mutations such as that shown by actual Xpert results
in 2013–2017 (Fig. 3C).
The MTBGT tool was developed to aid surveillance efforts of low- and middle-income
high RR-TB burden countries with likely fragmented data collection systems (Mazumdar,
Satyanarayana & Pai, 2019). Through facilitated continuous analysis of previous
historical and current RR-TB data, as well as clinical data from large aggregated ﬁles and
routine laboratory and periodic survey RDT results combined with WGS-derived data
from national surveillance programs and public data repositories, the MTBGT tool may
create a larger picture of the RS-TB and RR-TB burden in a country. The RS and RR-TB
counts and proportions and RDT probe reactions generated by the MTBGT tool may
contribute to an extensive database with years’ worth of data for continuous statistical
modeling analyses and surveillance investigations.
Potentially, the MTBGT tool may be integrated in the national TB diagnostic algorithm
through the existing information system and connectivity platform or the newly
implementedWHO cloud-based software (Dean, 2019). The prospective application of the
MTBGT tool may bridge and transform the Mtb data gap into action points for RR-TB
clinicians to provide appropriate care for the individual TB/RR-TB patient, and the
NTP, public health ofﬁcials, and policy makers to intervene at the population-level for
improved and sustained RR-TB control (Gardy & Loman, 2018). The MTBGT modules
could also be expanded to report non-RRDR RR-conferring mutations and include other
TB drugs—e.g. isoniazid, pyrazinamide, and ﬂuoroquinolones.
CONCLUSIONS
The MTBGT tool leverages improved access to next-generation sequencing technologies
in this genomic epidemiology era of TB, and complements Mtb WGS by rapidly
transforming WGS ﬁles that store genomic sequence variations to validated outputs of
the RR-TB RDTs. The prospective application of the MTBGT tool within a nationwide
genomic epidemiology program will bridge the Mtb data gap among routine RDT
data, research setting WGS, and periodic survey and continuous surveillance rpoB
sequencing and WGS data. This may result in facilitated continuous analysis of the
circulating RDT probes and underlying distribution of RR-conferring mutations in the
setting, and may help assess whether currently implemented RDT(s) serve the detection
of RR-TB cases in the country.
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